At the JP Morgan Health Conference, Swiss cancer giant Novartis has presented a corporate update, highlighting clinical and commercial progress while outlining 9 January 2024
Drug resistance specialist InMed has inked a deal with fellow Chinese firm Escugen, a clinical-stage antibody–drug conjugate (ADC) developer. 2 January 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.